ANXA1 and syringocystadenoma papilliferum: Serum AnxA1 level at admission was significantly lower in the non-SCAP group than in the SCAP group (240.76 [202.42–378.60]) vs. 441.91 [282.25–780.33] ng/mL, p < 0.001; Figure 1a).